Trademark: 97008640
Word
POWERED BY BIOHM
Status
Pending
Status Code
732
Status Date
Tuesday, April 9, 2024
Serial Number
97008640
Mark Type
4000
Filing Date
Thursday, September 2, 2021
Published for Opposition
Tuesday, August 16, 2022

Trademark Owner History
BIOHM HEALTH INC. - 1st New Owner After Publication
Biohm Health LLC - Owner At Publication

Classifications
5 Probiotic supplements; vitamin and mineral supplements; vitamin supplements; whey protein supplements; dietary supplement drink mixes; dietary supplement for eliminating toxins from the intestinal tract; enzyme food supplements; herbal supplements; mineral supplements; multi-vitamin preparations; natural herbal supplements; nutraceuticals for use as a dietary supplement; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplement shakes; nutritional supplements, namely, probiotic compositions; nutritional supplements, namely, carbohydrates in powdered form; powdered nutritional supplement concentrate; vitamin and mineral supplements in powder, tablet, liquid, capsule or spray form; mineral supplements in powder, tablet, liquid, capsule or spray form; dietary supplements in powder, tablet, liquid, capsule or spray form; food supplements providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; nutritional supplements for human consumption providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; herbal supplements for general health and well-being, namely, in powder, tablet, liquid, capsule or spray form; nutritional supplements, namely, probiotic compositions in the nature of a vaginal probiotic for the treatment and prevention of bacterial and fungal vaginal infection; nutraceuticals for the treatment and prevention of bacterial vaginosis, vaginal discharge and odors, for preventing the growth of undesirable micro-organisms that can cause vaginal discharge and odor, killing bacteria that cause bacterial vaginosis, and for maintaining a desirable microflora in the vaginal cavity; micro-organisms culture for medical use, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's Disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's Disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's Disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibers in the human organism; pharmaceutical products for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's Disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans; microbial and biological preparations for medical use, namely, probiotics, for improving the physical well-being of humans, namely, reducing inflammation and pain; dietary supplements for medical use and baby food containing microorganisms, namely, metabolites obtained from the processing of probiotic bacterial cultures; probiotic and nutritional and dietary supplements; antifungal preparations; antifungal creams for medical use; vaginal antifungal preparations; fungal extracts sold as a component ingredient of nutritional supplments and vitamins and bacterial probiotic supplements, and nutritional supplement for digestive health; nutritional supplement for combating digestive disorders such as Crohn's Disease, ulcerative colitis and irritable bowel syndrome; beverages containing probiotic compositions for use as a nutritional supplement; food supplements containing probiotic compositions; human food supplements containing probiotic compositions; animal food products containing probiotic compositions, namely, probiotic animal feed; dietary supplement drink mixes, namely, probiotic compositions in the form of mixes to added to beverages; dietary supplements in the nature of probiotic compositions for mixing with cereal; medical specimens collection kits for the collection of body fluids comprised of swabs for medical purposes, a sealable collection container and sample bag; medical specimens collection kits for the collection of body fluids comprised of swabs for medical purposes, a sealable collection container, sample bag, mailer envelope, ID sticker, and swab applicator; diagnostic biological testing kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; diagnostic genetic testing kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; diagnostic microbiota testing kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; medical specimen collection kits for the collection of body fluids comprised of medical specimen bags and cups

Trademark Events
Apr 10, 2024
Notice Of Approval Of Extension Request E-Mailed
Apr 9, 2024
Sou Extension 3 Granted
Apr 9, 2024
Sou Extension 3 Filed
Apr 9, 2024
Sou Teas Extension Received
Oct 13, 2023
Notice Of Approval Of Extension Request E-Mailed
Oct 11, 2023
Sou Extension 2 Granted
Oct 11, 2023
Sou Extension 2 Filed
Oct 11, 2023
Sou Teas Extension Received
Apr 21, 2023
Notice Of Approval Of Extension Request E-Mailed
Apr 20, 2023
Sou Extension 1 Granted
Apr 7, 2023
Sou Extension 1 Filed
Apr 19, 2023
Automatic Update Of Assignment Of Ownership
Apr 14, 2023
Case Assigned To Intent To Use Paralegal
Apr 7, 2023
Sou Teas Extension Received
Oct 11, 2022
Noa E-Mailed - Sou Required From Applicant
Aug 16, 2022
Official Gazette Publication Confirmation E-Mailed
Aug 16, 2022
Published For Opposition
Jul 27, 2022
Notification Of Notice Of Publication E-Mailed
Jul 14, 2022
Approved For Pub - Principal Register
Jul 13, 2022
Teas/Email Correspondence Entered
Jul 12, 2022
Correspondence Received In Law Office
Jul 12, 2022
Teas Response To Office Action Received
Jan 12, 2022
Notification Of Non-Final Action E-Mailed
Jan 12, 2022
Non-Final Action E-Mailed
Jan 12, 2022
Non-Final Action Written
Jan 10, 2022
Assigned To Examiner
Oct 15, 2021
New Application Office Supplied Data Entered

Trademark Alertz updated from USPTO on 2030-01-24